RESEARCH · TRACK LIST
The CJC-1295 Research Record, Study by Study
Mechanism, the human pharmacokinetic studies, the preserved-pulsatility finding, and the honest gaps — each claim logged to its source.
The Mechanism: GHRH Receptor to IGF-1
The short version of how CJC-1295 works is on the overview page; the mechanism in full begins at the GHRH receptor, a class B GPCR on pituitary somatotrophs coupled to an adenylate-cyclase system — the proximal signaling step characterized in purified somatotrophs decades before the analog existed [8]. Agonist binding drives Gs/cAMP/PKA signaling and CREB-mediated GH gene transcription; released GH then acts on hepatic GH receptors through JAK2/STAT5 to produce IGF-1.
Cryo-EM structures resolved how peptide agonists engage and activate the receptor, clarifying the active conformation that GHRH analogs stabilize [7]. A 2025 Nature Reviews Endocrinology review synthesizes the pharmacology of GHRH and its synthetic analogues — the class that includes CJC-1295, sermorelin, and tesamorelin — describing receptor signaling and the rationale for long-acting analog design [11]. The mechanism is well mapped; the human outcome data are thinner.
The Human Pharmacokinetic Studies
The defining human study dosed healthy adults aged 21 to 61 with single subcutaneous 30 or 60 micrograms/kg, recording dose-dependent 2- to 10-fold increases in mean plasma GH for six days or more and 1.5- to 3-fold increases in IGF-1 for nine to eleven days. After multiple doses, IGF-1 remained above baseline up to 28 days, and the estimated half-life was 5.8 to 8.1 days [1].
The rodent groundwork came first: a series of hGRF(1-29)-albumin bioconjugates was screened, and the lead — CJC-1295 — combined four DPP-IV-protective substitutions with covalent albumin binding, showing a 4-fold GH AUC increase over two hours versus the unconjugated peptide and plasma detection beyond 72 hours [2]. Together these two studies established both that the chemistry works and how long its effect lasts.
Does CJC-1295 Preserve GH Pulsatility?
Yes — preserved pulsatility is one of the most-cited findings in the record. In healthy men aged 20 to 40, a single subcutaneous dose of 60 or 90 micrograms/kg raised basal GH roughly 7.5-fold and lifted mean GH by about 46% and IGF-1 by about 45% one week later, while the frequency and magnitude of pulsatile GH secretion were unaltered [3].
The significance is mechanistic. A constant GHRH stimulus might have been expected to flatten GH into a steady leak, but the pituitary continued to fire in its native pulse pattern under continuous analog stimulation. That distinguishes a GHRH analog from a direct GH injection, which overrides the pulse entirely. The GH pulsatility findings are why the molecule is studied as a secretagogue rather than a hormone replacement.
CJC-1295 and Ipamorelin: The Two-Receptor Rationale
The pairing of CJC-1295 with ipamorelin rests on a two-receptor rationale: CJC-1295 is a GHRH analog acting on the GHRH receptor, while ipamorelin is a growth-hormone-releasing peptide (GHRP) acting on the separate ghrelin/GHS receptor. Co-administering a GHRH analog with a GHRP produces GH release greater than either agent alone, because the two pathways converge on the somatotroph through distinct upstream signals.
The mechanistic case is well established. What is limited is controlled human efficacy data for the specific combination in healthy adults. The published CJC-1295 pharmacokinetic figures cited here come from the analog dosed alone [1] [3]; community protocols that pair the two at fixed microgram doses are not derived from controlled trials. The combination is a research topic, not a validated regimen.
CJC-1295 Among GHRH Analogs (sermorelin, tesamorelin)
Comparing CJC-1295 vs sermorelin clarifies what the DAC chemistry adds. Sermorelin is hGRF(1-29) without protease-resistant engineering, so it is short-acting; CJC-1295 carries four substitutions and, in the DAC variant, an albumin tether that extends the half-life to days [1] [2]. Tesamorelin is the approved-drug benchmark in the class — a stabilized GHRH analog with an established human indication — making it the closest regulator-vetted comparator to the unapproved CJC-1295. The 2025 Nature Reviews Endocrinology review situates all three on the same pharmacological axis, differing mainly in stability and duration [11].
Reported and Theoretical Concerns
The CJC-1295 side effects discussed in the literature are largely theoretical, extrapolated from sustained GH/IGF-1 elevation rather than measured in long-term trials. GH-axis stimulation can cause fluid retention and edema through sodium reabsorption, and can affect insulin sensitivity. Epidemiology links higher IGF-1 to a modestly increased risk of certain cancers, which is the basis for caution around any sustained IGF-1 rise.
FDA briefing materials for the 2024 Pharmacy Compounding Advisory Committee cited immunogenicity and other safety concerns for GH secretagogues including CJC-1295; the committee did not recommend it for the 503A compounding bulks list, and it is not on that list. Human safety data on CJC-1295 itself remain limited to small early-phase studies [1] [3]. These are flagged gaps, not cleared questions; the regulatory status of CJC-1295 — unapproved and WADA-prohibited — is covered in full on the FAQ.
What the Research Describes
What the research describes — as distinct from what users expect — is sustained, dose-dependent rises in GH and IGF-1 over days following the long-acting DAC variant, and only a brief effect from the no-DAC form. A proteomic study in 11 healthy men found CJC-1295 shifted the serum proteome reproducibly, with an immunoglobulin/albumin-fragment signal correlating linearly with IGF-1 — candidate biomarkers of axis activation [5].
This is measured research output, not a human-use expectation, since CJC-1295 is unapproved and untested in long-term human trials.